Inside STAT: Psychiatry is buzzing with anticipation — and questions — about esketamine 

The FDA will decide soon on whether to improve esketamine, a nasal spray delivered with oral antidepressants to treat people with depression who haven’t responded to other therapies. The psychiatry field is buzzing with excitement — and in some cases, hesitation. Many experts are excited about the drug as an option for patients in dire need of new treatments, particularly because it could work quickly. But some experts aren’t convinced that there’s enough data on how well esketamine works and how it should be used in the long-term treatment of depression. I have the story here.